|
Synonyms: 9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Compound class:
Antibody
Comment: Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in [2], and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 [1].
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial. A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) [5]. |
| Immunopharmacology Comments |
| The rationale for targeting IFNα in SLE, and outcomes from anti-IFNα or anti-type I interferon receptor (IFNAR1) antibody therapies in SLE patients is discussed by Kalunian (2016) [3]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Failed Phase 2 clinical candidate for SLE. | |
